Different subsets of γδ T cells display differential expression of immune checkpoint receptors (ICRs) and have distinct ...

While this panel has grown in recent years, many experts believe additional biomarkers should also be incorporated as ...

Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.

The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...

In a Nov. 21 note, he maintained a “Speculative Buy” rating and C$5.25 (US$4.00) target.

The firm plans to submit results from the Phase III OptiTROP-Lung05 trial to regulators in China, seeking approval for sac-TMT and Keytruda in PD-L1-positive patients.

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a ...

New NSCLC guideline updates outline expanded perioperative immunotherapy, adjuvant targeted therapy, and consolidation ...

Jazz Pharmaceuticals plc stock jumped on positive Ziihera trial results. Click for my updated look at JAZZ stock and see why ...

Beyond a cancer cell’s genetic blueprint, the expression levels of certain proteins on its surface is emerging as a collection of critical, actionable biomarkers. Instead of looking for a mutated gene ...

The therapeutic landscape for hepatocellular carcinoma (HCC) has been revolutionized by the advent of molecular targeted therapies and immune ...